Arnatar Therapeutics
PrivateLast Round
Series A
Apr 8, 2024
Total Funding Raised
$66.45M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Arnatar Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A round in April 2024.
Arnatar Therapeutics is a biotechnology company that develops RNA-based therapies using its proprietary DARGER platform to silence disease drivers or restore protein function for the treatment of cardiometabolic, liver, kidney, and central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arnatar Therapeutics Comparables
Compare Arnatar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanegene Bio | 78% | |
| Orfonyx Bio | 75% | |
| Estuary Biotherapeutics | 74% |
For institutional investors. Book with your work email.
Arnatar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 8, 2024 | ||||
| Seed | Sep 19, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Arnatar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jifeng Ventures | Series A |
| New Alliance Capital | Series A |
| Legend Star | Series A |
| Bencao Capital | Series A |
| Eight Roads Ventures | Series A |
| Transfar Group | Series A |
| Huajin Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 23, 2026
Grew 43% QoQ from 14 to 20 employees.
- Jul 28, 2026
Grew 55% QoQ, from 11 to 17 employees.
For institutional investors. Book with your work email.
Arnatar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Arnatar Therapeutics's valuation, stock price, and market status.
Is Arnatar Therapeutics a public or private company?
Arnatar Therapeutics is a private company.
What is the current stock price of Arnatar Therapeutics?
Arnatar Therapeutics is a private company, so its shares have no public market price. Caplight tracks Arnatar Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arnatar Therapeutics worth (valuation)?
Valuation information for Arnatar Therapeutics is not publicly available.
Can I buy Arnatar Therapeutics stock?
Arnatar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arnatar Therapeutics's last funding round?
Arnatar Therapeutics's most recent funding round was Series A on April 8, 2024.
Who are the main investors in Arnatar Therapeutics?
Key investors in Arnatar Therapeutics include Bencao Capital, Eight Roads Ventures, Apricot Capital.
Will Arnatar Therapeutics IPO soon?
No public IPO plans have been announced for Arnatar Therapeutics.
How can I track Arnatar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Arnatar Therapeutics's shares on secondary markets.